Tissue | Expression Dynamics | Abbreviation |
Breast | | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00092594 | Colorectum | CRC | ribonucleotide metabolic process | 75/2078 | 385/18723 | 7.83e-07 | 5.04e-05 | 75 |
GO:00091855 | Colorectum | CRC | ribonucleoside diphosphate metabolic process | 30/2078 | 106/18723 | 8.96e-07 | 5.71e-05 | 30 |
GO:00725215 | Colorectum | CRC | purine-containing compound metabolic process | 79/2078 | 416/18723 | 1.15e-06 | 6.75e-05 | 79 |
GO:00196934 | Colorectum | CRC | ribose phosphate metabolic process | 75/2078 | 396/18723 | 2.36e-06 | 1.13e-04 | 75 |
GO:00060905 | Colorectum | CRC | pyruvate metabolic process | 29/2078 | 106/18723 | 2.88e-06 | 1.33e-04 | 29 |
GO:19035803 | Colorectum | CRC | positive regulation of ATP metabolic process | 15/2078 | 38/18723 | 5.82e-06 | 2.28e-04 | 15 |
GO:00459813 | Colorectum | CRC | positive regulation of nucleotide metabolic process | 16/2078 | 43/18723 | 7.05e-06 | 2.64e-04 | 16 |
GO:19005443 | Colorectum | CRC | positive regulation of purine nucleotide metabolic process | 16/2078 | 43/18723 | 7.05e-06 | 2.64e-04 | 16 |
GO:00061655 | Colorectum | CRC | nucleoside diphosphate phosphorylation | 26/2078 | 99/18723 | 2.04e-05 | 5.93e-04 | 26 |
GO:00091325 | Colorectum | CRC | nucleoside diphosphate metabolic process | 30/2078 | 124/18723 | 2.78e-05 | 7.52e-04 | 30 |
GO:00469395 | Colorectum | CRC | nucleotide phosphorylation | 26/2078 | 101/18723 | 2.98e-05 | 7.82e-04 | 26 |
GO:00061103 | Colorectum | CRC | regulation of glycolytic process | 15/2078 | 45/18723 | 6.10e-05 | 1.35e-03 | 15 |
GO:00160524 | Colorectum | CRC | carbohydrate catabolic process | 34/2078 | 154/18723 | 6.37e-05 | 1.39e-03 | 34 |
GO:00097435 | Colorectum | CRC | response to carbohydrate | 49/2078 | 253/18723 | 7.07e-05 | 1.51e-03 | 49 |
GO:00335004 | Colorectum | CRC | carbohydrate homeostasis | 49/2078 | 259/18723 | 1.29e-04 | 2.46e-03 | 49 |
GO:00091175 | Colorectum | CRC | nucleotide metabolic process | 81/2078 | 489/18723 | 1.45e-04 | 2.65e-03 | 81 |
GO:00460345 | Colorectum | CRC | ATP metabolic process | 51/2078 | 277/18723 | 1.92e-04 | 3.30e-03 | 51 |
GO:00425934 | Colorectum | CRC | glucose homeostasis | 48/2078 | 258/18723 | 2.27e-04 | 3.78e-03 | 48 |
GO:00067535 | Colorectum | CRC | nucleoside phosphate metabolic process | 81/2078 | 497/18723 | 2.48e-04 | 4.06e-03 | 81 |
GO:00060915 | Colorectum | CRC | generation of precursor metabolites and energy | 80/2078 | 490/18723 | 2.55e-04 | 4.16e-03 | 80 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZBTB20 | SNV | Missense_Mutation | | c.1090N>A | p.Glu364Lys | p.E364K | Q9HC78 | protein_coding | deleterious(0.03) | probably_damaging(0.959) | TCGA-A8-A06Q-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
ZBTB20 | SNV | Missense_Mutation | novel | c.1864A>G | p.Ile622Val | p.I622V | Q9HC78 | protein_coding | tolerated(0.06) | possibly_damaging(0.727) | TCGA-AC-A62Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ZBTB20 | SNV | Missense_Mutation | novel | c.1824C>G | p.Cys608Trp | p.C608W | Q9HC78 | protein_coding | deleterious(0) | probably_damaging(0.973) | TCGA-B6-A0I5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ZBTB20 | SNV | Missense_Mutation | | c.1120A>C | p.Ser374Arg | p.S374R | Q9HC78 | protein_coding | deleterious(0) | probably_damaging(0.969) | TCGA-BH-A18Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ZBTB20 | SNV | Missense_Mutation | rs779910215 | c.2155N>A | p.Val719Ile | p.V719I | Q9HC78 | protein_coding | tolerated_low_confidence(0.1) | probably_damaging(0.984) | TCGA-D8-A1Y1-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | PD |
ZBTB20 | insertion | Nonsense_Mutation | novel | c.1688_1689insAGAACGTTGCTTAAGATAAACTTTGCCTTCTTTGCAGGGTAATGTAA | p.Ala564GlufsTer6 | p.A564Efs*6 | Q9HC78 | protein_coding | | | TCGA-A8-A08T-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
ZBTB20 | insertion | Frame_Shift_Ins | novel | c.1171_1172insGATCTCGATGTCGCTGTAGCCA | p.Glu391GlyfsTer22 | p.E391Gfs*22 | Q9HC78 | protein_coding | | | TCGA-AN-A0AS-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
ZBTB20 | insertion | In_Frame_Ins | novel | c.1261_1262insATCCCCTTGCAACTGATGTCACCTGCAGCATGTCAA | p.Pro421delinsHisProLeuAlaThrAspValThrCysSerMetSerThr | p.P421delinsHPLATDVTCSMST | Q9HC78 | protein_coding | | | TCGA-AO-A0JE-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
ZBTB20 | insertion | Frame_Shift_Ins | novel | c.1822_1823insATATTCTTGTGGAAGAGAAAAAGAAAAAGAAATGGAGGGTGGGG | p.Cys608TyrfsTer25 | p.C608Yfs*25 | Q9HC78 | protein_coding | | | TCGA-B6-A0I5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ZBTB20 | deletion | Frame_Shift_Del | novel | c.284delN | p.Asn95ThrfsTer12 | p.N95Tfs*12 | Q9HC78 | protein_coding | | | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |